Nina Balanchivadze, MD
Hematology & Oncology · Norfolk, VANPI 1215225552
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,454 of the $16,347 with a category attached, or 82.3%. 11 manufacturers reported payments, led by Gilead at 37.1% of the total. Reporting peaked in 2024 at $7,314 and has fallen 55.1% since, to $3,284 in 2025. Among hematology & oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $480.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Merck$3K
- Novartis$3K
- Stemline Therapeutics Inc.$2K
- Daiichi Sankyo Inc.$1K
- Array Biopharma Inc$150
- plus $247 from 5 others
Across 14 payments — averaging $61,483 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$594K
- AstraZeneca$266K
What the payments were for
- Consulting fees$13,45482%
- Speaking & faculty fees$1501%
- Travel & lodging$1,2027%
- Food & beverage$1,0436%
- Other$4993%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 12 | $6,067 |
| Merck | 6 | $3,423 |
| Novartis | 7 | $2,870 |
| Stemline Therapeutics Inc. | 1 | $2,480 |
| Daiichi Sankyo Inc. | 1 | $1,110 |
| Array Biopharma Inc | 1 | $150 |
| Seagen Inc. | 1 | $111 |
| Astrazeneca UK Limited | 1 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,347 in reported general payments places this provider in the 90th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 14 | $229,071 |
| Exemestane | 54 | $8,690 |
| Letrozole | 347 | $5,746 |
| Anastrozole | 59 | $970 |
| Dexamethasone | 17 | $526 |
| Raloxifene Hcl | 27 | $513 |
| Tamoxifen Citrate | 24 | $449 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $349 |
| Ondansetron Hcl | 11 | $111 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Norfolk
- Gary SimmonsNorfolk$82K
- Michael DansoNorfolk$47K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Mark FlemingHampton$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.